-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network News, August 4, August 2, Luoxin Pharmaceutical issued an announcement stating that its subsidiary Shandong Yuxin's ambroxol hydrochloride spray was approved for production, and it was the first domestically marketed ambroxol hydrochloride spray product.
.
Ambroxol is a commonly used expectorant.
According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
.
.
Ambroxol is a commonly used expectorant.
According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
.
Ambroxol hydrochloride was developed by Boehringer Ingelheim.
It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
.
It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
.
According to data from Menet.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
22% of the total sales.
Market share
.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
22% of the total sales.
Market share
.
Sales of terminal ambroxol in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ambroxol products currently on the market in China include oral solutions, tablets, injections, inhalation solutions and other dosage forms
.
Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
.
The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
.
.
Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
.
The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
.
As a very classic and commonly used expectorant in clinical practice, ambroxol hydrochloride has come to many pharmaceutical companies to develop new dosage forms for it
.
Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
.
.
Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
.
In addition, ambroxol hydrochloride oral regular-release dosage forms and injections have been included in the third and fourth batches of centralized procurement, respectively.
The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
.
The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
.
Selection of National Centralized Procurement of Ambroxol
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
Pharmaceutical Network News, August 4, August 2, Luoxin Pharmaceutical issued an announcement stating that its subsidiary Shandong Yuxin's ambroxol hydrochloride spray was approved for production, and it was the first domestically marketed ambroxol hydrochloride spray product.
.
Ambroxol is a commonly used expectorant.
According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
.
.
Ambroxol is a commonly used expectorant.
According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
.
Ambroxol hydrochloride was developed by Boehringer Ingelheim.
It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
.
It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
.
According to data from Menet.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
22% of the total sales.
Market share
.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
22% of the total sales.
Market share
.
Sales of terminal ambroxol in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ambroxol products currently on the market in China include oral solutions, tablets, injections, inhalation solutions and other dosage forms
.
Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
.
The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
.
.
Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
.
The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
.
As a very classic and commonly used expectorant in clinical practice, ambroxol hydrochloride has come to many pharmaceutical companies to develop new dosage forms for it
.
Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
.
.
Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
.
In addition, ambroxol hydrochloride oral regular-release dosage forms and injections have been included in the third and fourth batches of centralized procurement, respectively.
The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
.
The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
.
Selection of National Centralized Procurement of Ambroxol
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
Pharmaceutical Network News, August 4, August 2, Luoxin Pharmaceutical issued an announcement stating that its subsidiary Shandong Yuxin's ambroxol hydrochloride spray was approved for production, and it was the first domestically marketed ambroxol hydrochloride spray product.
.
Ambroxol is a commonly used expectorant.
According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
.
.
Ambroxol is a commonly used expectorant.
According to data from Meinenet, the terminal sales of ambroxol in China's public medical institutions will exceed 4 billion yuan in 2020
.
Ambroxol hydrochloride was developed by Boehringer Ingelheim.
It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
.
It has the properties of promoting the elimination of mucous phlegm and dissolving secretions.
It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting sputum production and improving respiratory conditions
.
According to data from Menet.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
22% of the total sales.
Market share
.
Hospital hospital hospitalcom, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal ambroxol sales exceeded 4 billion yuan, and Boehringer Ingelheim accounted for 21.
22% of the total sales.
Market share
.
Sales of terminal ambroxol in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ambroxol products currently on the market in China include oral solutions, tablets, injections, inhalation solutions and other dosage forms
.
Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
.
The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
.
Child, child, kid.
Ambroxol hydrochloride spray is the first ambroxol hydrochloride spray product to be marketed in China.
It is suitable for children aged 2-6 with thick sputum and difficulty in expectoration
.
The product is a metered valve spray administration, with the characteristics of accurate dosage and good drug compliance for children, and is a special drug for children
.
As a very classic and commonly used expectorant in clinical practice, ambroxol hydrochloride has come to many pharmaceutical companies to develop new dosage forms for it
.
Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
.
Toddler, toddler, toddler.
Just in March of this year, the production of ambroxol hydrochloride drops by Poinsettia Pharmaceuticals was approved by the State Food and Drug Administration.
The product is also an exclusive formulation in China and is suitable for people who have thick sputum that is not easy to cough up, including young children
.
In addition, ambroxol hydrochloride oral regular-release dosage forms and injections have been included in the third and fourth batches of centralized procurement, respectively.
The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
.
The market scale of related dosage forms will shrink, and exclusive dosage forms will not be affected temporarily
.
Selection of National Centralized Procurement of Ambroxol
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
Pharmaceutical Purchasing medicine medicine procurement procurement 
